Celgene (CELG) EPS & PE Ratio History
Current and historical earning per share (EPS) and price to earnings (PE) ratio for Celgene (CELG) over the last 10 years. The current PE ratio for Celgene as of November 21, 2017 is 16.33.
|Medical||Medical - Biomedical and Genetics||$82.275B||$11.229B|
|Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.|